CAGR of 9.3% Projected for Myelodysplastic Syndrome Drugs Market From 2025 to 2029
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Much Is the Global Myelodysplastic Syndrome Drugs Market Valued at Present and by 2029?
The market size for drugs treating myelodysplastic syndrome has witnessed robust growth in the recent past. The market is projected to expand from $2.25 billion in 2024 to $2.44 billion in 2025, registering a compound annual growth rate (CAGR) of 8.3%. Several factors have contributed to the growth seen during the historic period, including an aging population, medical advancements in diagnostics, cases of MDS related to chemotherapy, a rise in cancer survivors, and progress in clinical research and drug development.
In the forthcoming years, the market for myelodysplastic syndrome drugs is predicted to experience robust expansion. It is projected to reach “$3.48 billion by 2029 with a compound annual growth rate (CAGR) of 9.3%. This projected expansion in the forecast period can be ascribed to factors such as increasing elderly population, advancement in target treatments, improved comprehension of disease mechanisms, heightened awareness and early detection, and broadening scope in oncology research. Key developments anticipated during the forecast period encompass optimization of erythropoiesis-stimulating agents, combined therapies, growing emphasis on iron chelation therapy, regulatory approvals and access to the market, as well as patient-centered care models.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10675&type=smp
#What Drivers Are Influencing Growth In The Myelodysplastic Syndrome Drugs Market?
The growth of the myelodysplastic syndrome (MDS) drug market is anticipated to skyrocket in the upcoming years with the rise in MDS incidence. MDS poses as a collective of disorders, characterized by irregular formation and maturation of blood cells within the bone marrow, a type of blood cancer majorly impacting the manufacturing of healthy blood cells. Drugs for myelodysplastic syndrome play a significant role in MDS treatment and include medications that can either suppress or modulate the immune system, reducing the necessity for red blood cell transfusions. As an example, the American Journal of Managed Care, a US-centric magazine, estimated in October 2022, that MDS prevalence in America ranges from 60,000 to 175,000 cases. Thus, the surge in myelodysplastic syndrome incidence is fueling the expansion of the MDS drug market.
The myelodysplastic syndrome drugs market covered in this report is segmented –
1) By Therapeutic Class: Immunomodulatory Drugs, Hypomethylating Agents, Anti-anemics
2) By Type of Syndrome: Refractory Cytopenia With Multilineage Dysplasia, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Ringed Sideroblasts
3) By Route of Administration: Oral, Parenteral
4) By Applications: Original, Generics
5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers
Subsegments:
1) By Immunomodulatory Drugs: Thalidomide, Lenalidomide, Pomalidomide
2) By Hypomethylating Agents: Azacitidine, Decitabine, Guadecitabine
3) By Anti-anemics: Erythropoiesis-Stimulating Agents (ESAs), Iron Supplements, Blood Transfusion Products
Which Emerging Trends And Strategic Shifts Are Shaping The Myelodysplastic Syndrome Drugs Market?
Leading businesses in the myelodysplastic syndrome drugs market are focusing on the development of telomerase inhibitors to target the telomerase enzyme. The aim is to decelerate the disease progression by restraining the unregulated division of abnormal cells. The significance of telomerase inhibitors in myelodysplastic syndrome drugs is due to their function – they inhibit the telomerase enzyme, thus curbing the spread of irregular cells, potentially enhancing patient results. For instance, Geron Corporation, an American biotech firm, introduced rytelo (imetelstat), a telomerase inhibitor approved by the FDA for intravenous use in adults diagnosed with low to intermediate-1 risk myelodysplastic syndromes (LR-MDS) and transfusion dependent anemia who are not responding or unsuitable for ESA in June 2024. Rytelo not only provides enduring transfusion independence and elevated hemoglobin levels but also caters to a previously unaddressed need within the myelodysplastic syndrome drugs market, all while maintaining a manageable safety profile.
Which Companies Play A Key Role In The Development Of The Myelodysplastic Syndrome Drugs Market?
Major companies operating in the myelodysplastic syndrome drugs market include Amgen Inc., Celgene Corporation, Otsuka Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Lupin Ltd., Onconova Therapeutics Inc., Sun Pharmaceutical Industries Limited, FibroGen Inc., Aprea Therapeutics, Bayer AG, Bristol Myers Squibb, Celator Pharmaceuticals, Crystal Genomics Inc., AbbVie Inc., Astex Pharmaceuticals Inc., Geron Co., Hikma Pharmaceuticals plc, Jazz Pharmaceuticals Inc., Mylan NV, Novartis AG, Sandoz Inc., Syros Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Acceleron Pharma Inc., Agios Pharmaceuticals Inc., Incyte Corporation, Array Biopharma Inc., MEI Pharma Inc.
What Are The Key Regional Developments Shaping The Myelodysplastic Syndrome Drugs Market?
North America was the largest region in the Myelodysplastic syndrome drugs market in 2024.Asia-Pacific is expected to be the fastest growing region in the global myelodysplastic syndrome drugs market report during the forecast period. The regions covered in the myelodysplastic syndrome drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=10675&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
